• EPZ-6438 in Combination Epigenetic Cancer Therapy: Mechanism

  2026-04-30

  Explore how EPZ-6438, a potent EZH2 inhibitor, drives breakthroughs in epigenetic cancer research and combinational therapy strategies. Uncover unique mechanistic insights, practical assay recommendations, and data-driven perspectives distinct from prior coverage.

• EdU Imaging Kits (488): Transforming S-Phase Analysis in Onc

  2026-04-30

  This thought-leadership article explores the mechanistic, translational, and strategic impact of EdU Imaging Kits (488) for quantifying S-phase DNA synthesis, with a focus on liver cancer research and the emerging biomarker HAUS1. Drawing on recent literature and workflow evidence, we highlight how APExBIO’s click chemistry platform advances cell proliferation assays, supports high-integrity imaging, and accelerates biomarker-driven discovery. Protocol guidance, competitive insights, and a forward-looking perspective are included.

• PKM2 Inhibitor (Compound 3k): Redefining Selective Cancer Me

  2026-04-29

  Explore how PKM2 inhibitor (compound 3k) advances selective cancer cell metabolism disruption and illuminates the metabolic-immune interface. This article provides a deep scientific analysis and protocol guidance, distinguishing it from existing workflow- and scenario-focused resources.

• Zosuquidar (LY335979): Precision P-gp Inhibition in MDR Canc

  2026-04-29

  Zosuquidar (LY335979) 3HCl empowers oncology researchers to reverse multidrug resistance by selectively inhibiting P-glycoprotein efflux pumps. This guide details experimental workflows, troubleshooting strategies, and protocol parameters—bridging bench evidence and clinical translation for robust drug sensitization in cancer models.

• Angiotensin II in Vascular Remodeling & Hypertrophy Research

  2026-04-28

  Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) is the gold-standard experimental catalyst for dissecting vascular smooth muscle cell hypertrophy and cardiovascular remodeling. This guide unpacks evidence-backed workflows, advanced troubleshooting, and unique mechanistic insights, leveraging APExBIO’s rigorously validated peptide.

• Saquinavir in HIV Research: Advanced Permeability Modeling a

  2026-04-28

  Discover how Saquinavir, a leading HIV protease inhibitor, enables advanced drug permeability modeling and translational research beyond conventional antiretroviral workflows. Explore unique protocol insights and real-world applications informed by cutting-edge biomimetic chromatography.

• cgSHAPE-seq Maps SARS-CoV-2 RNA Ligand Sites for Targeted De

  2026-04-27

  This study introduces chemical-guided SHAPE sequencing (cgSHAPE-seq), a sequencing-based method for mapping ligand binding sites on structured RNA. Applying cgSHAPE-seq, the authors identify and validate the binding pocket of coumarin-based RNA-degrading chimeras in the SARS-CoV-2 5' UTR, advancing strategies for targeted viral RNA degradation.

• Zosuquidar (LY335979): Overcoming Multidrug Resistance in Ca

  2026-04-27

  Zosuquidar (LY335979) 3HCl is redefining cancer research by selectively inhibiting the P-glycoprotein efflux pump, restoring chemosensitivity in multidrug-resistant models. Explore optimized protocols, troubleshooting insights, and translational applications powered by APExBIO’s trusted quality.

• Pesticide Drift Assessment: UAV vs. Knapsack Sprayer Using R

  2026-04-26

  This study provides the first robust field comparison of pesticide spray drift from unmanned aerial vehicle (UAV) and traditional electric knapsack sprayer (EKS) applications, using Rhodamine B as a quantitative fluorescent tracer. The findings reveal significantly greater drift distances and deposition rates with UAVs, offering new baseline data for environmental risk assessment and regulatory guidance.

• PLK1-Mediated Regulation of p31comet in Mitotic Checkpoint D

  2026-04-25

  This study uncovers how Polo-like kinase 1 (PLK1) regulates p31comet through direct phosphorylation, suppressing its ability to disassemble mitotic checkpoint complexes and thus ensuring proper mitotic checkpoint fidelity. These findings clarify a key layer of cell cycle control and provide mechanistic rationale for using selective PLK1 inhibitors to probe mitotic progression and checkpoint inactivation.

• Trichostatin A in Epigenetic Cancer Research: Protocols & In

  2026-04-24

  Trichostatin A (TSA) stands out as a robust HDAC inhibitor for precise epigenetic modulation in cancer research. This article delivers actionable workflows, troubleshooting strategies, and evidence-backed tips for maximizing TSA’s utility in cell-based and in vivo studies, drawing from recent in-depth studies and APExBIO’s trusted product quality.

• Applied Workflows with Nicotinamide Adenine Dinucleotide (NA

  2026-04-24

  Nicotinamide Adenine Dinucleotide (NAD+) empowers researchers to dissect metabolic signaling, autophagy, and DNA repair with precision. This article synthesizes the latest mechanistic insights and hands-on troubleshooting to help you design robust, reproducible experiments using APExBIO’s high-purity NAD+.

• Circ_0001944 Modulation of FXR/TLR4 and Ferroptosis in NiONP

  2026-04-23

  This study reveals how hsa_circ_0001944 mitigates nickel oxide nanoparticle (NiONP)-induced collagen deposition in hepatic stellate cells by regulating the FXR/TLR4 signaling pathway and ferroptosis. The findings provide mechanistic clarity on the interplay between non-coding RNAs, nuclear receptor signaling, and cell death pathways in liver fibrosis models.

• Tiamulin (Thiamutilin): Molecular Selectivity, Ionophore Int

  2026-04-23

  Explore the molecular mechanisms and unique ionophore interactions of Tiamulin (Thiamutilin), a leading veterinary antibiotic for pigs and poultry. Gain new insights into its clinical and experimental advantages, protocol optimization, and emerging anti-inflammatory potential.

• Viral-Mediated RIPK3 Degradation Regulates Necroptosis and I

  2026-04-22

  This study reveals how certain orthopoxviruses encode a viral inducer of RIPK3 degradation (vIRD) that hijacks the host ubiquitin-proteasome system to degrade RIPK3, thereby suppressing necroptosis and modulating virus-induced inflammation. The findings provide mechanistic insight into viral immune evasion and highlight the central role of proteasome-dependent pathways in host-pathogen interactions.

15820 records 1/1055 page Next 12345 下5页 Last page